Wednesday, September 4, 2013

Vol. 19, No. 17

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 17 September 3, 2013
(The next issue will be on September 16, 2013)
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
None Submitted for this issue.
__________________________________________________________
UPCOMING MEETINGS & EVENTS
General info on upcoming meetings of interest:
http://tf7.org/meetings.htm

ISTH also maintains a list of upcoming meetings of interest:
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":

Amarnath A, Lenin V, Archunan G (2013) Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome.
Pharmacogn Mag 9:264-270.

Bolton SA, Sutton JC, Anumula R, Bisacchi GS, Jacobson B, Slusarchyk WA, . . . Seiler SM (2013) Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold. Bioorg Med Chem Lett.

Brenden N, Madeyski-Bengtson K, Martinsson K, Svard R, Albery-Larsdotter S, Granath B, . . . Lovgren A (2013) A triple-transgenic immunotolerant mouse model. J Pharm Sci 102:1116-1124.

Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C (2013) Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thromb Haemost 110.

Demissie A, Shahani L, Khan A, Desai M (2013) Acquired haemophilia A initially diagnosed as angioedema. BMJ Case Rep 2013.

Duga S, Salomon O (2013) Congenital Factor XI Deficiency: An Update.
Semin Thromb Hemost.

Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limon P, . . .
Pierangeli SS (2013) A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis.

Etscheid M, Muhl L, Pons D, Jukema JW, Konig H, Kanse SM (2012) The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity.
Thromb Res 130:935-941.

Ghosh M, Ahmad S, Jian A, Li B, Smith RW, Helm KM, . . . Reynolds SD
(2013) Human Tracheobronchial Basal Cells: Normal Versus Remodeling/Repairing Phenotypes in vivo and in vitro. Am J Respir Cell Mol Biol.

Gissel M, Orfeo T, Foley JH, Butenas S (2012) Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 130:948-955.

Gruber SN, Volles DF (2013) Usefulness of laboratory values in predicting effectiveness of recombinant factor VIIa in surgical patients with bleeding. Am J Health Syst Pharm 70:1528-1532.

Haffner E, Pietsch U, Fosel T, Lindemann W (2013) [Treatment of a pregnant patient after multiple trauma: rare combination with thrombotic thrombocytopenic purpura]. Anaesthesist 62:125-129.

Hemmeryckx B, Hoylaerts MF, Deloose E, Van Hove CE, Fransen P, Bult H, Lijnen HR (2013) Age-associated pro-inflammatory adaptations of the mouse thoracic aorta. Thromb Haemost 110.

Henn LW, Esmailian F (2013) Repair of a Large Main Pulmonary Artery Aneurysm in a 71-Year-Old Jehovah's Witness Patient. Tex Heart Inst J 40:350-352.

Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA (2013) Rapid regression of atherosclerosis with MTP inhibitor treatment.
Atherosclerosis 227:125-129.

Hoffman M, Monroe DM (2012) The multiple roles of tissue factor in wound healing. Front Biosci (Schol Ed) 4:713-721.

Hvas CL, Fenger-Eriksen C, Hoyer S, Sorensen B, Tonnesen E (2013) Hypercoagulation following brain death cannot be reversed by the neutralization of systemic tissue factor. Thromb Res.

Krudysz-Amblo J, Jennings ME, 2nd, Knight T, Matthews DE, Mann KG, Butenas S (2013) Disulfide reduction abolishes tissue factor cofactor function. Biochim Biophys Acta 1830:3489-3496.

Lagneaux L, Philippart P, Meuleman N, Stamatopoulos B, Najar M, Pieters K, . . . Bron D (2013) In vivo production of mesenchymal stromal cells after injection of autologous platelet-rich plasma activated by recombinant human soluble tissue factor in the bone marrow of healthy volunteers. Tissue Eng Part A.

Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc'h N, . . . Reverdiau P (2013) Beneficial role of overexpression of
TFPI-2 on tumour progression in human small cell lung cancer. FEBS Open Bio 3:291-301.

Lester PA, Diaz JA, Shuster KA, Henke PK, Wakefield TW, Myers DD
(2012) Inflammation and thrombosis: new insights. Front Biosci (Schol
Ed) 4:620-638.

Long M, Wagner D, Maslach-Hubbard A, Pasko D, Baldridge P, Annich G
(2013) Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review. Perfusion.

Lopez-Vilchez I, Galan AM, Hernandez MR, Caballo C, Roque M, Diaz-Ricart M, . . . Escolar G (2012) Platelet-associated tissue factor enhances platelet reactivity and thrombin generation in experimental studies in vitro. Thromb Res 130:e294-300.

Margaritis P (2012) Gene-based continuous expression of FVIIa for the treatment of hemophilia. Front Biosci (Schol Ed) 4:287-299.

Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A (2013) Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol.

Otsuka T (2013) [Mechanism and risk factors of cardiogenic thromboembolism in patients with atrial fibrillation]. Nihon Rinsho 71:36-40.

Pabinger I, Thaler J, Ay C (2013) Biomarkers for prediction of venous thromboembolism in cancer. Blood.

Palkovits J, Novacek G, Kollars M, Hron G, Osterode W, Quehenberger P, . . . Weltermann A (2013) Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis 7:222-229.

Palsson R, Vidarsson B, Gudmundsdottir BR, Larsen OH, Ingerslev J, Sorensen B, Onundarson PT (2013) Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries. Platelets.

Rayner BS, Figtree GA, Sabaretnam T, Shang P, Mazhar J, Weaver JC, .
. . Bhindi R (2013) Selective inhibition of the master regulator transcription factor egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction. J Am Heart Assoc 2:e000023.

Ruiz-Saez A (2013) Occurrence of Thrombosis in Rare Bleeding Disorders. Semin Thromb Hemost.

Tardy-Poncet B, Piot M, Brunet D, Chapelle C, Bonardel M, Mismetti P, . . . Tardy B (2012) TFPI resistance related to inherited or acquired protein S deficiency. Thromb Res 130:925-928.

Teitel JM, Sholzberg M (2013) Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies. Blood Rev 27:103-109.

Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, . . .
Pabinger I (2013) Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest 43:277-285.

Voils SA, Baird B (2012) Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 130:833-840.

Young G, Auerswald G, Jimenez-Yuste V, Lambert T, Morfini M, Santagostino E, Blanchette V (2012) PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 130:864-870.

Zentai C, Grottke O, Spahn DR, Rossaint R (2013) Nonsurgical techniques to control massive bleeding. Anesthesiol Clin 31:41-53.
http://www.ncbi.nlm.nih.gov/pubmed/23351533
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________

Vol. 19, No. 16

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 16 August 16, 2013
(The next issue will be on September 3, 2013)
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
None Submitted for this issue.
__________________________________________________________
UPCOMING MEETINGS & EVENTS
General info on upcoming meetings of interest:
http://tf7.org/meetings.htm

ISTH also maintains list of upcoming meetings of interest:
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":

Amarnath A, Lenin V, Archunan G (2013) Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome.
Pharmacogn Mag 9:264-270.

Bolton SA, Sutton JC, Anumula R, Bisacchi GS, Jacobson B, Slusarchyk WA, . . . Seiler SM (2013) Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold. Bioorg Med Chem Lett.

Brenden N, Madeyski-Bengtson K, Martinsson K, Svard R, Albery-Larsdotter S, Granath B, . . . Lovgren A (2013) A triple-transgenic immunotolerant mouse model. J Pharm Sci 102:1116-1124.

Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C (2013) Microparticle-associated tissue factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. Thromb Haemost 110.

Demissie A, Shahani L, Khan A, Desai M (2013) Acquired haemophilia A initially diagnosed as angioedema. BMJ Case Rep 2013.

Duga S, Salomon O (2013) Congenital Factor XI Deficiency: An Update.
Semin Thromb Hemost.

Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limon P, . . .
Pierangeli SS (2013) A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis.

Etscheid M, Muhl L, Pons D, Jukema JW, Konig H, Kanse SM (2012) The Marburg I polymorphism of factor VII activating protease is associated with low proteolytic and low pro-coagulant activity.
Thromb Res 130:935-941.

Ghosh M, Ahmad S, Jian A, Li B, Smith RW, Helm KM, . . . Reynolds SD
(2013) Human Tracheobronchial Basal Cells: Normal Versus Remodeling/Repairing Phenotypes in vivo and in vitro. Am J Respir Cell Mol Biol.

Gissel M, Orfeo T, Foley JH, Butenas S (2012) Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res 130:948-955.

Gruber SN, Volles DF (2013) Usefulness of laboratory values in predicting effectiveness of recombinant factor VIIa in surgical patients with bleeding. Am J Health Syst Pharm 70:1528-1532.

Haffner E, Pietsch U, Fosel T, Lindemann W (2013) [Treatment of a pregnant patient after multiple trauma: rare combination with thrombotic thrombocytopenic purpura]. Anaesthesist 62:125-129.

Hemmeryckx B, Hoylaerts MF, Deloose E, Van Hove CE, Fransen P, Bult H, Lijnen HR (2013) Age-associated pro-inflammatory adaptations of the mouse thoracic aorta. Thromb Haemost 110.

Henn LW, Esmailian F (2013) Repair of a Large Main Pulmonary Artery Aneurysm in a 71-Year-Old Jehovah's Witness Patient. Tex Heart Inst J 40:350-352.

Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA (2013) Rapid regression of atherosclerosis with MTP inhibitor treatment.
Atherosclerosis 227:125-129.

Hoffman M, Monroe DM (2012) The multiple roles of tissue factor in wound healing. Front Biosci (Schol Ed) 4:713-721.

Hvas CL, Fenger-Eriksen C, Hoyer S, Sorensen B, Tonnesen E (2013) Hypercoagulation following brain death cannot be reversed by the neutralization of systemic tissue factor. Thromb Res.

Krudysz-Amblo J, Jennings ME, 2nd, Knight T, Matthews DE, Mann KG, Butenas S (2013) Disulfide reduction abolishes tissue factor cofactor function. Biochim Biophys Acta 1830:3489-3496.

Lagneaux L, Philippart P, Meuleman N, Stamatopoulos B, Najar M, Pieters K, . . . Bron D (2013) In vivo production of mesenchymal stromal cells after injection of autologous platelet-rich plasma activated by recombinant human soluble tissue factor in the bone marrow of healthy volunteers. Tissue Eng Part A.

Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc'h N, . . . Reverdiau P (2013) Beneficial role of overexpression of
TFPI-2 on tumour progression in human small cell lung cancer. FEBS Open Bio 3:291-301.

Lester PA, Diaz JA, Shuster KA, Henke PK, Wakefield TW, Myers DD
(2012) Inflammation and thrombosis: new insights. Front Biosci (Schol
Ed) 4:620-638.

Long M, Wagner D, Maslach-Hubbard A, Pasko D, Baldridge P, Annich G
(2013) Safety and efficacy of recombinant activated factor VII for refractory hemorrhage in pediatric patients on extracorporeal membrane oxygenation: a single center review. Perfusion.

Lopez-Vilchez I, Galan AM, Hernandez MR, Caballo C, Roque M, Diaz-Ricart M, . . . Escolar G (2012) Platelet-associated tissue factor enhances platelet reactivity and thrombin generation in experimental studies in vitro. Thromb Res 130:e294-300.

Margaritis P (2012) Gene-based continuous expression of FVIIa for the treatment of hemophilia. Front Biosci (Schol Ed) 4:287-299.

Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A (2013) Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol.

Otsuka T (2013) [Mechanism and risk factors of cardiogenic thromboembolism in patients with atrial fibrillation]. Nihon Rinsho 71:36-40.

Pabinger I, Thaler J, Ay C (2013) Biomarkers for prediction of venous thromboembolism in cancer. Blood.

Palkovits J, Novacek G, Kollars M, Hron G, Osterode W, Quehenberger P, . . . Weltermann A (2013) Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis 7:222-229.

Palsson R, Vidarsson B, Gudmundsdottir BR, Larsen OH, Ingerslev J, Sorensen B, Onundarson PT (2013) Complementary effect of fibrinogen and rFVIIa on clotting ex vivo in Bernard-Soulier syndrome and combined use during three deliveries. Platelets.

Rayner BS, Figtree GA, Sabaretnam T, Shang P, Mazhar J, Weaver JC, .
. . Bhindi R (2013) Selective inhibition of the master regulator transcription factor egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction. J Am Heart Assoc 2:e000023.

Ruiz-Saez A (2013) Occurrence of Thrombosis in Rare Bleeding Disorders. Semin Thromb Hemost.

Tardy-Poncet B, Piot M, Brunet D, Chapelle C, Bonardel M, Mismetti P, . . . Tardy B (2012) TFPI resistance related to inherited or acquired protein S deficiency. Thromb Res 130:925-928.

Teitel JM, Sholzberg M (2013) Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies. Blood Rev 27:103-109.

Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, . . .
Pabinger I (2013) Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest 43:277-285.

Voils SA, Baird B (2012) Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 130:833-840.

Young G, Auerswald G, Jimenez-Yuste V, Lambert T, Morfini M, Santagostino E, Blanchette V (2012) PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 130:864-870.

Zentai C, Grottke O, Spahn DR, Rossaint R (2013) Nonsurgical techniques to control massive bleeding. Anesthesiol Clin 31:41-53.
http://www.ncbi.nlm.nih.gov/pubmed/23351533
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________

Vol. 19, No. 15

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 15 July 31, 2013
(The next issue will be on August 15, 2013)
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
AUTHORS: Tavoosi N, Smith SA, Davis-Harrison RL, and Morrissey JH
TITLE:  Factor VII and Protein C are Phosphatidic Acid-Binding Proteins
JOURNAL: Biochemistry
ABSTRACT: Seven proteins in the human blood clotting cascade bind, via their GLA (gamma-carboxyglutamate-rich) domains, to membranes containing exposed phosphatidylserine (PS), although with membrane binding affinities that vary by three orders of magnitude. Here we employed Nanodiscs of defined phospholipid composition to quantify the phospholipid binding specificities of these seven clotting proteins. All bound preferentially to nanobilayers in which PS headgroups contained L-serine versus D-serine. Surprisingly, however, nanobilayers containing phosphatidic acid (PA) bound substantially more of two of these proteins-factor VIIa and activated protein C-than did equivalent bilayers containing PS. Consistent with this finding, liposomes containing PA supported higher proteolytic activity by factor VIIa and activated protein C toward their natural substrates (factors X and Va, respectively) than did PS-containing liposomes. Moreover, treating activated human platelets with phospholipase D enhanced the rates of factor X activation by factor VIIa in the presence of soluble tissue factor. We hypothesize that factor VII and protein C bind preferentially to the monoester phosphate of PA because of its accessibility and higher negative charge compared to the diester phosphates of most other phospholipids. We further found that phosphatidylinositol 4-phosphate, which contains a monoester phosphate attached to its myo-inositol headgroup, also supported enhanced enzymatic activity of factor VIIa and activated protein C. We conclude that factor VII and protein C bind preferentially to monoester phosphates, which may have implications for the function of these proteases in vivo.

SUBMITTED BY: Jim Morrissey <jhmorris@illinois.edu
__________________________________________________________
UPCOMING MEETINGS & EVENTS
2013 ASH Annual Meeting will be held in New Orleans, LA, December 7-10, 2013. Abstract deadline is August 8, 2013. More info:
    ***   ***   ***   ***
2014 Gordon Research Conference on Plasminogen Activation & Extracellular Proteolysis will be held February 9-14, 2014 in Ventura, CA. More info:
    ***   ***   ***   ***
Thrombosis and Hemostasis Summit of North America (THSNA) meeting will be held in Chicago, IL, April 10-12, 2014. Early registration deadline December 1, 2013; abstract submission starts September 2013.
More info:
    ***   ***   ***   ***
2014 ATVB Meeting will be held May 1-3, 2014 in Toronto, Canada. More info:
    ***   ***   ***   ***
7th Symposium on Hemostasis will be held at the Carolina Inn, Chapel Hill, NC, May 15-17, 2014. Focus will include tissue factor, coagulation proteases and their role in hemostasis and thrombosis, as well as interplay between coagulation and inflammation More info:
    ***   ***   ***   ***
2014 Hemostasis Gordon Research Conference will be held July 27 to August 1, 2014, in Waterville, NH. It will be preceded by a two-day Gordon Research Seminar July 26-27 for postdocs and graduate students. More info:
    ***   ***   ***   ***
General info on upcoming meetings of interest:

ISTH also has a list of upcoming meetings of interest:
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":

  (2013) Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire Int 22:155-159.

Awad E, Khan S, Sokolikova B, Brunner P, Olcaydu D, Wojta J, . . .
Uhrin P (2013) Cold induces ROS-production and activation of the NF-kappa B response in endothelial cells and inflammation in vivo. J Thromb Haemost.

Bakhtiari K, Kamphuisen PW, Mancuso ME, Hamulyak K, Schutgens RE, Santagostino E, Meijers JC (2013) Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients. Br J Haematol.

Barone I, Meccariello G, Cazzato L, Capalbo SF, Matteo M, Greco P
(2013) Management of platelet storage pool disease during pregnancy with recombinant factor VIIa. Eur J Obstet Gynecol Reprod Biol.

Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS, Mackman N, Iyer RV (2013) Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res.

Brand HS, Veerman EC (2013) Saliva and wound healing. Chin J Dent Res 16:7-12.

Chen VM (2013) Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. Semin Thromb Hemost 39:40-47.

Chen VM, Hogg PJ (2013) Encryption and decryption of tissue factor. J Thromb Haemost 11 Suppl 1:277-284.

Cho AH, Khosla R (2013) A Case of Massive Airway Clotting After Use of Activated Factor VII for Massive Hemoptysis: Management With Flexible Bronchoscopy and Cryoadhesion. J Bronchology Interv Pulmonol 20:276-277.

Cole M, Bromberg M (2013) Tissue factor as a novel target for treatment of breast cancer. Oncologist 18:14-18.

Denas G, Pengo V (2013) Investigational anticoagulants for hematological conditions: a new generation of therapies. Expert Opin Investig Drugs.

Emekli-Alturfan E, Yarat A, Caliskan-Ak E, Pisiriciler R, Kuru B, Noyan U (2013) Determination of storage time of saliva samples obtained from patients with and without chronic periodontitis for the comparison of some biochemical and cytological parameters. J Clin Lab Anal 27:261-266.

Gushchina LV, Yasmeen R, Ziouzenkova O (2013) Moderate vitamin A supplementation in obese mice regulates tissue factor and cytokine production in a sex-specific manner. Arch Biochem Biophys.

Huang ZJ, Zhao Y, Luo WY, You J, Li SW, Yi WC, . . . Luo Q (2013) Targeting the Vasculature of Colorectal Carcinoma with a Fused Protein of (RGD)3-tTF. ScientificWorldJournal 2013:637086.

Jiang MH, Wang ZY, Yu ZQ, Su J, Cao LJ, Zhang W (2013) [Identification and functional analysis of a novel missense mutation Ser250Phe underlying congenital coagulation factor deficiency].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 30:152-156.

Kambas K, Chrysanthopoulou A, Vassilopoulos D, Apostolidou E, Skendros P, Girod A, . . . Mitroulis I (2013) Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis.

Kocaturk B, Versteeg HH (2013) Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill. J Thromb Haemost 11 Suppl 1:285-293.

Korhonen TK, Haiko J, Laakkonen L, Jarvinen HM, Westerlund-Wikstrom B
(2013) Fibrinolytic and coagulative activities of. Front Cell Infect Microbiol 3:35.

Lima LG, Monteiro RQ (2013) Activation of blood coagulation in
cancer: implications for tumor progression. Biosci Rep.

Lippi G, Favaloro EJ, Cervellin G (2013) Massive posttraumatic
bleeding: epidemiology, causes, clinical features, and therapeutic management. Semin Thromb Hemost 39:83-93.

Lupu C, Herlea O, Tang H, Lijnen RH, Lupu F (2013) Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia. J Thromb Haemost 11:142-148.

Mathias M, Tunstall O, Khair K, Liesner R (2013) Management of surgical procedures in children with severe FV deficiency: experience of 13 surgeries. Haemophilia 19:256-258.

Mita-Mendoza NK, van de Hoef DL, Lopera-Mesa TM, Doumbia S, Konate D, Doumbouya M, . . . Fairhurst RM (2013) A potential role for plasma uric acid in the endothelial pathology of Plasmodium falciparum malaria. PLoS One 8:e54481.

Monroe DM, Hoffman M, Roberts HR, Hedner U (2013) Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia.

Nakabayashi T, Gotoh Y, Kamada N, Fujioka M, Ishihara T, Hirabayashi A, Sato H (2013) Characterization of in vitro biotransformation of the new oral anticoagulants, the factor VIIa inhibitors AS1927819-00 and AS1932804-00. Pharmazie 68:406-413.

Nakabayashi T, Gotoh Y, Kamada N, Fujioka M, Ishihara T, Hirabayashi A, Sato H (2013) Pharmacokinetics of the amidine prodrug of a novel oral anticoagulant factor VIIa inhibitor (AS1924269-00) in rats.
Pharmazie 68:349-354.

Neufeld EJ, Saxena K, Kessler CM, Cooper DL (2013) Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008). Pediatr Blood Cancer 60:1178-1183.

Ng C, Silliman CC, Pearl G, Smith W, Manco-Johnson M, Wang M (2013) Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor. Pediatr Blood Cancer 60:E23-25.

Ngo Sack F, Galinat H, Egreteau PY, Mollard LM, Fortin H, Berthou C, . . . Pan-Petesch B (2013) Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis. Haemophilia 19:e93-94.

Nie XM, Su LX, Xu RX, Guo YL, Zhou YJ, Li JJ (2013) Kruppel-like factor 2 might mediate the rapamycin-induced arterial thrombosis in
vivo: implications for stent thrombosis in patients. Chin Med J
(Engl) 126:2636-2640.

Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M, Kihara S, . .
. Minami S (2013) Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques.
Atherosclerosis 226:373-377.

Oku K, Amengual O, Zigon P, Horita T, Yasuda S, Atsumi T (2013) Essential role of the p38 mitogen-activated protein kinase pathway in tissue factor gene expression mediated by the phosphatidylserine-dependent antiprothrombin antibody. Rheumatology (Oxford).

Peyvandi F, Garagiola I, Seregni S (2013) Future of coagulation factor replacement therapy. J Thromb Haemost 11 Suppl 1:84-98.

Peyvandi F, Menegatti M, Palla R (2013) Rare Bleeding Disorders:
Worldwide Efforts for Classification, Diagnosis, and Management.
Semin Thromb Hemost.

Rao B, Gao Y, Zhou Q, Xiao P, Xia S, Ma J, . . . Wang J (2013) A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model. J Cancer Res Clin Oncol 139:1015-1023.

Sakowicz A, Fendler W, Lelonek M, Sakowicz B, Pietrucha T (2013) Genetic polymorphisms and the risk of myocardial infarction in patients under 45 years of age. Biochem Genet 51:230-242.

Schulz C, Engelmann B, Massberg S (2013) Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J Thromb Haemost 11 Suppl 1:233-241.

Sergeeva AM, Mazurok VA, Zakirov II, Kichigin VA (2013) [Recombinant activated factor VII use for the bleeding implications prevention during central venous catheterization in pediatric patients with acute leucosis and thrombocytopenia]. Anesteziol Reanimatol:18-21.

Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, . . . Saito H (2013) Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture
(MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report. Haemophilia 19:330-337.

Shrestha C, Ito T, Kawahara KI, Shrestha B, Yamakuchi M, Hashiguchi T, Maruyama I (2013) Saturated fatty acid palmitate induces extracellular release of histone H3: A possible mechanistic basis for high-fat diet-induced inflammation and thrombosis. Biochem Biophys Res Commun.

Sridharan V, Tripathi P, Sharma S, Corry PM, Moros EG, Singh A, . . .
Boerma M (2013) Effects of late administration of pentoxifylline and tocotrienols in an image-guided rat model of localized heart irradiation. PLoS One 8:e68762.

Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM, Iversen N
(2013) TFPIalpha and TFPIbeta are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. J Hematol Oncol 6:5.

Sternberg Z, Ghanim H, Gillotti KM, Tario JD, Jr., Munschauer F, Curl R, . . . Dandona P (2013) Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood.
Atherosclerosis 229:338-347.

Tavoosi N, Smith SA, Davis-Harrison RL, Morrissey JH (2013) Factor VII and Protein C are Phosphatidic Acid-Binding Proteins. Biochemistry.

Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczynska M, Podolec P, Undas A (2013) Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. J Thorac Cardiovasc Surg.

Vadivel K, Agah S, Messer AS, Cascio D, Bajaj MS, Krishnaswamy S, . .
. Bajaj SP (2013) Structural and functional studies of gamma-carboxyglutamic acid domains of factor VIIa and activated Protein C: role of magnesium at physiological calcium. J Mol Biol 425:1961-1981.

Xu Y, Zhang X, Zhao Y, Zhao L, Qiu H, Wu D (2013) Successful treatment of a patient with acquired haemophilia A with a combination of a low-dose rituximab and recombinant human FVIIa. Haemophilia 19:e95-96.

Yang L, Rezaie AR (2013) Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa. J Biol Chem 288:12692-12698.

Zhang TL, Liu B, Zhang P, Xing XH, Meng YS, Lan QL (2013) [A family with hereditary coagulation factor deficiency]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 30:126.

Zhao Y, Fu Y, Hu J, Liu Y, Yin X (2013) The effect of tissue factor pathway inhibitor on the expression of monocyte chemotactic protein-3 and IkappaB-alpha stimulated by tumour necrosis factor-alpha in cultured vascular smooth muscle cells. Arch Cardiovasc Dis 106:4-11.

Zhu H, Liang B, Li R, Li J, Lin L, Ma S, Wang J (2013) Activation of coagulation, anti-coagulation, fibrinolysis and the complement system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50.
http://www.ncbi.nlm.nih.gov/pubmed/23517393
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________

Vol. 19, No. 14

TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 14 July 15, 2013
(The next issue will be on August 1, 2013)
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
None Submitted for this issue.
__________________________________________________________
UPCOMING MEETINGS & EVENTS
General info on upcoming meetings of interest:
http://tf7.org/meetings.htm
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":

Bao Y, Jin Y, Chivukula P, Zhang J, Liu Y, Liu J, . . . Yu L (2013) Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm Res 30:342-351.

Ben-Hadj-Khalifa S, Nguyen P, Mahjoub T, Hezard N (2012) Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor Xa-activated human monocyte model. Eur Cytokine Netw 23:87-92.

Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P, Phillips J, . .
. Tran H (2012) How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. Intern Med J 42:1243-1250.

Cai X, Freedman SB, Witting PK (2013) Serum amyloid A stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multi-kinase inhibitor BIBF1120. Clin Exp Pharmacol Physiol.

Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R (2013) Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes. Thromb Res.

Chaari M, Bouhlel R, Kallel S, Aidi Z, Makni F, Gerotziafas GT, . . .
Kallel C (2012) [Post partum acquired hemophilia A with fatal
outcome: a case report]. Ann Biol Clin (Paris) 70:741-746.

Frumkin K (2013) Rapid Reversal of Warfarin-Associated Hemorrhage in the Emergency Department by Prothrombin Complex Concentrates. Ann Emerg Med.

Giordano P, Lassandro G, Tesse R, Longo S, Valente F, Cappiello AR, Coppola A (2013) Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia. Blood Transfus 11:143-147.

Girolami A, Berti de Marinis G, Vettore S, Girolami B (2013) Congenital FVII deficiency and pulmonary embolism: a critical appraisal of all reported cases. Clin Appl Thromb Hemost 19:55-59.

Glunz PW, Zhang X, Zou Y, Delucca I, Nirschl AH, Cheng X, . . .
Priestley ES (2013) Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors. Bioorg Med Chem Lett.

Gonzalez F, Kirwan JP, Rote NS, Minium J (2013) Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl Thromb Hemost 19:66-72.

Hoving S, Heeneman S, Gijbels MJ, Te Poele JA, Visser N, Cleutjens J, . . . Stewart FA (2012) Irradiation induces different inflammatory and thrombotic responses in carotid arteries of wildtype C57BL/6J and atherosclerosis-prone ApoE(-/-) mice. Radiother Oncol 105:365-370.

Ip HL, Chan AY, Ng KC, Soo YO, Wong LK (2013) Case Report: A 70-Year-Old Man with Undiagnosed Factor VII Deficiency Presented with Acute Ischemic Stroke. J Stroke Cerebrovasc Dis.

Kandane-Rathnayake RK, Willis CD, Beiles CB, Bourke BM, Cameron PA, McCall P, Phillips LE (2013) Investigation of outcomes following recombinant activated FVII use for refractory bleeding during abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 45:617-625.

Kidd L, Mackman N (2013) Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia. J Vet Emerg Crit Care (San Antonio) 23:3-13.

Korber MK, Langer E, Ziemer S, Perzborn E, Gericke C, von Heymann C
(2013) Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban: An In Vitro Study. Clin Appl Thromb Hemost.

Kortchinsky T, Vigue B, Samama CM (2013) [Reversal for heparins and new anticoagulant treatments]. Ann Fr Anesth Reanim 32:37-49.

Kutcher ME, Ferguson AR, Cohen MJ (2013) A principal component analysis of coagulation after trauma. J Trauma Acute Care Surg 74:1223-1229; discussion 1229-1230.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, . . .
Crook T (2013) Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol 133:1278-1285.

Maroney SA, Hansen KG, Mast AE (2013) Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Curr Opin Hematol.

Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, Peyvandi F, van Heerde WL (2013) Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb Res.

Meade TW, Stirling Y (2012) The Northwick Park Heart Studies:
contrasts between the two factor VII assays used. J Thromb Haemost 10:482-484.

Mousa SA (2013) Comparative pharmacodynamic assessment of the antiangiogenesis activity of heparin and low-molecular-weight heparin
fractions: structure-function relationship. Clin Appl Thromb Hemost 19:48-54.

Nagakura T, Tabata K, Kira K, Hirota S, Clark R, Matsuura F, Hiyoshi H (2013) Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding. Thromb Res.

Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, . . . Lisman T (2013) Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. Br J Haematol.

Rautou PE, Mackman N (2013) Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol 6:91-101.

Tagliaferri A, Franchini M (2013) The expanding role of prophylaxis with recombinant activated factor VII. Blood Transfus 11:12-13.

Thompson JF (2013) Recombinant activated factor VII and aortic surgery. Eur J Vasc Endovasc Surg 45:626.

Tian Y, Ma S, Lin B, Kou J, Yu B (2013) Anti-thrombotic activity of DT-13, a saponin isolated from the root tuber of Liriope muscari.
Indian J Pharmacol 45:283-285.

Toutouzas K, Synetos A, Nikolaou C, Tsiamis E, Tousoulis D, Stefanadis C (2012) Matrix metalloproteinases and vulnerable atheromatous plaque. Curr Top Med Chem 12:1166-1180.

Winch PD, Naguib AN, Bradshaw JR, Galantowicz M, Tobias JD (2013) Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa. Pediatr Cardiol 34:119-124.

Winnik S, Stein S, Matter CM (2012) SIRT1 - an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 10:693-696.

Yamashita A, Zhao Y, Zhao S, Matsuura Y, Sugita C, Iwakiri T, . . .
Asada Y (2013) Arterial F-Fluorodeoxyglucose Uptake Reflects Balloon Catheter-Induced Thrombus Formation and Tissue Factor Expression via Nuclear Factor-kappaB in Rabbit Atherosclerotic Lesions. Circ J.
http://www.ncbi.nlm.nih.gov/pubmed/23832535
__________________________________________________________
ABOUT TRIGGER
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.

DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________